TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04185831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: PD-L1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: MTOR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: MEK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: PARP inhibitor
Study: NCT02715466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balanced gelatine solution
Description: Gelaspan combined with Sterofundin ISO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Balanced electrolyte solution
Description: Sterofundin ISO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balanced electrolyte solution
Description: Sterofundin ISO
Study: NCT01856374

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus-eluting stent (Cypher SelectTM, Cordis, Miami, FL)
Description: Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; Xience Prime® vs. Cypher SelectTM and pravastatin 20mg vs. atorvastatin 40mg.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent(Xience Prime®, Abbott Vascular, Santa Claea, CA)
Description: Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; Xience Prime® vs. Cypher SelectTM and pravastatin 20mg vs. atorvastatin 40mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin 20mg
Description: 2x2 randomization by the treatment of dyslipidemia (In patients of dyslipidemia: pravastatin 20mg/day vs. atorvastatin 40mg and the types of the implanted cypher vs xience.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40mg
Description: 2x2 randomization by the treatment of dyslipidemia (In patients of dyslipidemia: pravastatin 20mg/day vs. atorvastatin 40mg and the types of the implanted cypher vs xience.
Study: NCT02162901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice-Class with IVR Calls
Description: The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone call over a period of 12 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Random-Class with IVR calls
Description: The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Random-Class only
Description: The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through a printed workbook.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice-DVD with IVR calls
Description: The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After watching a DVD at home to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Random-DVD with IVR calls
Description: The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After watching a DVD at home to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
Study: NCT02970175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin administration
Description: Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchoscopy under local anesthesia
Description: Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: bronchoscopy under local anesthesia
Description: Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy sampling
Description: Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biopsy sampling
Description: Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
Study: NCT00931151

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Postprandial metabolic and functional measures
Description: After ingestion of a high fat meal containing the different protein sources, the subjects undergo a series of measures of endothelial dysfunction and blood and urine sampling for the assessment of proinflammatory cytokines levels and metabolomics determinations.
Study: NCT02655913

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Supportive care
Description: Supportive care focuses on helping patients get relief from symptoms such as nausea, pain, fatigue, or shortness of breath,etc.
Study: NCT02258477

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sequence 1
Description: 100 calorie beverage during week 1; 10 calorie beverage during week 2; control beverage beverage during week 3; 50 calorie beverage during week 4.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sequence 2
Description: Control beverage during week 1; 100 calorie beverage during week 2; 50 calorie beverage during week 3; 10 calorie beverage during week 4.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sequence 3
Description: 50 calorie beverage during week 1; control beverage during week 2; 10 calorie beverage during week 3; 100 calorie beverage during week 4.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sequence 4
Description: 10 calorie beverage during week 1; 50 calorie beverage during week 2; 100 calorie beverage during week 3; control beverage during week 4.
Study: NCT00355082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamotrigine, 300 mg/day
Description: 300 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamotrigine, 250 mg/day
Description: 250 mg/day
Study: NCT03934502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A), within 30 minutes after start of a light meal (Treatment B), 1 hour prior to a low-fat meal (Treatment C), or 2 hours after start of a low-fat meal (Treatment D).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A), within 30 minutes after start of a light meal (Treatment B), 1 hour prior to a low-fat meal (Treatment C), or 2 hours after start of a low-fat meal (Treatment D).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A), within 30 minutes after start of a light meal (Treatment B), 1 hour prior to a low-fat meal (Treatment C), or 2 hours after start of a low-fat meal (Treatment D).
Study: NCT02655913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive care
Description: Supportive care focuses on helping patients get relief from symptoms such as nausea, pain, fatigue, or shortness of breath,etc.
Study: NCT03934502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A), within 30 minutes after start of a light meal (Treatment B), 1 hour prior to a low-fat meal (Treatment C), or 2 hours after start of a low-fat meal (Treatment D).
Study: NCT00965523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Eribulin mesylate 1.4 mg/m\^2 intravenous infusion (IV) given over 2 to 5 minutes on Day 1 and 8 every 21 days.
Study: NCT02165150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheelchair-bound Senior Elastic Band exercise program
Description: three times per week, 40 minutes per practice
Study: NCT04504045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: As part of a 6-drug cocktail caffeine 100 mg tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP1A2 activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: As part of a 6-drug cocktail efavirenz 50 mg coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2B6 activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: As part of a 6-drug cocktail losartan 12.5 mg coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2C9 activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazol
Description: As part of a 6-drug cocktail Omeprazol 10 mg enteric-coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2C19 activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: As part of a 6-drug cocktail metoprolol 12.5 mg release tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2D6 activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: As part of a 6-drug cocktail midazolam 2 mg oral solution will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP3A4 activity.
Study: NCT03085563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide
Description: Nitrous oxide will be delivered in one of two ways, using the titration method or rapid infusion method. Which ever method is used will be recorded. When using the titration method, starting at 20%, nitrous oxide will be added in 10% increments every 60 seconds until the ideal level of sedation has been met (not to exceed 70% nitrous oxide). Using the rapid infusion method, after the proper flow rate has been achieved with oxygen, the flowmeter will be increased to obtain 50% concentration of nitrous oxide. After 2-3 minutes if the patient does not have adequate sedation, nitrous oxide concentration will be increased to 70%.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Intranasal midazolam with mucosal atomizer device administration will follow the Children's Hospital Colorado (CHCO) established policy 'Intranasal Administration (atomization) of Medications'. As per standard of care, each patient will receive a standardized dose of 0.4mg/kg (maximum dose of 10mg) of intranasal midazolam with the mucosal atomizer device for all procedures.
Study: NCT01226745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4641
Description: Subjects will be administered with ONO-4641 at a dose of 0.15 milligram (mg) in the core study will be administered with ONO-4641 0.15 mg in this extension study for a duration of 225 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4641
Description: Subjects will be administered with ONO-4641 at a dose of 0.10 mg in the core study will be administered with ONO-4641 0.10 mg in this extension study for a duration of 225 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4641
Description: Subjects will be administered with ONO-4641 at a dose of 0.05 mg in the core study will be administered with ONO-4641 0.05 mg in this extension study for a duration of 225 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4641
Description: Subjects will receive placebo in the core study will be administered with ONO-4641 0.15 mg in this extension study for a duration of 225 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4641
Description: Subjects will receive placebo in the core study will be administered with ONO-4641 0.10 mg in this extension study for a duration of 225 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4641
Description: Subjects will receive placebo in the core study will be administered with ONO-4641 0.05 mg in this extension study for a duration of 225 weeks.
Study: NCT03414307

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracerebral catheter placement
Description: Image guided stereotactic placement of intra-hemorrhage catheters to evacuate intra-cerebral hemorrhage

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted intracerebral catheter
Description: ROSA is a robotic device with trajectory planning software that can be used to aid in planning multiple trajectories to large, irregular clots, and aids in navigating into and out of the cerebral hematoma with minimum human error.
Study: NCT00704990

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc, Magnesium, Vitamin B6, Vitamin C (Compound Natural Health Product for ADHD)
Description: Weight based dosing of a chewable natural health product containing 15-35 mg zinc citrate, 150-350 mg magnesium lactate, 30-70 mg pyridoxine hydrochloride and 150-350 mg calcium ascorbate. Participants will take weight based dose two times during the day with meals for a 10 week period
Study: NCT00779844

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bariatric coelioscopic surgical procedure
Description: total intra-venous anesthesia (propofol and remifentanil) being delivered using a close-loop system with the Bispectral Index as the single input for the controller

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: supra-umbilical coelioscopic surgical procedure
Description: total intra-venous anesthesia (propofol and remifentanil) being delivered using a closed-loop system with the Bispectral Index as the single input for the controller
Study: NCT00267020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1200 milligrams (mg) loading dose then 500 mg, orally, daily, six 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000 milligrams/square meter (mg/m\^2), intravenously on Days 1, 8 and 15 per cycle, six 28-day cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: 1000 milligrams/square meter (mg/m\^2), intravenously on Days 1, 8 and 15 per cycle, six 28-day cycles
Study: NCT04622488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Potassium
Description: - In the form of Insitu gel system can be applied as solution or suspension that undergoes gelation after administration. Applied once inside the root canal after chemo-mechanical preparation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Potassium
Description: - In the form of Insitu gel system can be applied as solution or suspension that undergoes gelation after administration. Applied once inside the root canal after chemo-mechanical preparation.
Study: NCT03755245

Intervention type: OTHER
Group type: OTHER
Intervention: [68Ga]Ga-DOTA-Siglec-9
Description: Vascular Adhesion Protein 1 (VAP-1) targeted radiopharmaceutical
Study: NCT00293475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Given IA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate
Description: Given IV
Study: NCT03673475

Intervention type: PROCEDURE
Intervention: Assessment of fluid responsiveness
Description: assessment of intravascular volume status using pleth variebility index and internal jugular vein distensibility in major abdominal surgery
Study: NCT03176303

Intervention type: DEVICE
Intervention: SpinalStim
Description: PEMF osteogenesis stimulator
Study: NCT00832923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEPAC
Description: The proposed enhancement of the IMPACT DC intervention will consist of three key components: (1) an enhanced IMPACT DC Asthma Clinic visit; (2) short-term case management to increase the rate of primary care follow-up visits in the first month after the IMPACT DC Asthma Clinic visit; and (3) training in an asthma care toolkit to improve communication around asthma care with the child's primary care provider.
Study: NCT04307186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoquatrane (BAY1747846)
Description: Solution for IV injection, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadovist/Gadavist)
Description: Solution for IV injection, single dose
Study: NCT01456000

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EAS-AC (HeartLight)
Description: Pulmonary vien isolation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm Ablation
Description: Treatment with standard ablation.
Study: NCT02106468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone tablet 5mg
Description: This group included 15 patients who received prednisone (Delta-cortene Fort®, Lepetit, Carmano, Melano, Italy) at 40mg /day (8 tablets/day in divided dose , 4 tablet at morning and 4 at evening) for 6 weeks then 20mg/day for 2 week then to 10 mg/day for 2 week, and finally to 5 mg /day for the last 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 soft capsules 1000 mg
Description: This group included 15 patients who received Omega-3 soft gelatin capsules 1000 mg (Super Omega; Technopharma, Cairo, Egypt). The patients received instruction to take one capsule three times daily for 3 months.
Study: NCT03146169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training group
Description: The training workshop includes four two-hour sessions:~Session one - a knowledge, self-efficacy, and motivation enhancement session at baseline; Session two - an interpersonal communication and leadership skills session at one week; Session three - a motivation enhancement session at one month Session four - an experience sharing session at three months
Study: NCT02461121

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HLA mismatched stem cell
Description: HLA mismatched donor G-CSF mobilized peripheral stem cell infused 24 hours (day 0) after the completion of chemotherapy

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: HLA matched stem cell
Description: HLA matched donor G-CSF mobilized peripheral stem cell infused after the conditioning reginmen
Study: NCT03496935

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tunneled versus non-tunneled dialysis catheter insertion
Description: The study participants will be randomized either to tunneled or non-tunneled dialysis catheter insertion to commence renal replacement therapy for an acute kidney injury requiring either continuous or intermittent dialysis in the ICU.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tunneled versus non-tunneled dialysis catheter insertion
Description: The study participants will be randomized either to tunneled or non-tunneled dialysis catheter insertion to commence renal replacement therapy for an acute kidney injury requiring either continuous or intermittent dialysis in the ICU.
Study: NCT02484235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT
Description: Group training with HIIT 3 times per week during 10 sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT
Description: Group training with HIIT 3 times per week during 10 sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength
Description: Group training with strength exercises 3 times per week during 10 sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength
Description: Group training with strength exercises 3 times per week during 10 sessions
Study: NCT02038959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Visits
Description: Virtual visits will be completed using HIPAA-compliant video conferencing software from SBR Health and Vidyo, designed specifically for use in the healthcare industry. The software is available for Windows and Mac OS, as well as iOS devices (iPad and iPhone).
Study: NCT00915473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivicaine
Description: 2.5 mL 0.5% bupivicaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 2.75 mL normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 0.5 mL 20 mg methylprednisolone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lidocaine
Description: 0.25 mL 1% lidocaine